Uncategorized
Publisher Correction: Lung and liver editing by lipid nanoparticle delivery of a stable CRISPR–Cas9 ribonucleoprotein
Nature Biotechnology, Published online: 18 June 2026; doi:10.1038/s41587-026-03221-1
Publisher Correction: Lung and liver editing by lipid nanoparticle delivery of a stable CRISPR–Cas9 ribonucleoprotein
Uncategorized
Opinion: Why the space in ‘health care’ matters
Below is a lightly edited, AI-generated transcript of the “First Opinion Podcast” interview with Sarah Mupo. Be sure to sign up for the weekly “First Opinion Podcast” on Apple Podcasts, Spotify, or wherever you get your podcasts. Get alerts about each new episode by signing up for the “First Opinion Podcast” newsletter. And don’t forget to sign up for the First Opinion newsletter, delivered every Sunday.
Torie Bosch: In recent years, there’s been a quiet shift in medicine. I’m not talking about a new drug or a new insurance headache. I’m talking about the way we write “health care.” Historically, it’s been two words. But increasingly, people, especially in the industry, have changed it to one word. At STAT, perhaps no linguistic decision is as important as: Should “health care” be one word or two?
Below is a lightly edited, AI-generated transcript of the “First Opinion Podcast” interview with Sarah Mupo. Be sure to sign up for the weekly “First Opinion Podcast” on Apple Podcasts, Spotify, or wherever you get your podcasts. Get alerts about each new episode by signing up for the “First Opinion Podcast” newsletter. And don’t forget to sign up for the First Opinion newsletter, delivered every Sunday.
Torie Bosch: In recent years, there’s been a quiet shift in medicine. I’m not talking about a new drug or a new insurance headache. I’m talking about the way we write “health care.” Historically, it’s been two words. But increasingly, people, especially in the industry, have changed it to one word. At STAT, perhaps no linguistic decision is as important as: Should “health care” be one word or two?
Uncategorized
Denali sells FDA voucher for $195M to support neurodegenerative pipeline
Denali Therapeutics is the latest company to sell a priority review fast pass for an elevated price after the program was renewed earlier this year.
Uncategorized
US launches investigation into German drug pricing, citing unfair R&D burden
The U.S. government has argued that it pays too much of biopharma R&D costs, demanding that other high-income countries contribute fairly to global innovation efforts.
-
Uncategorized9 years agoThese ’90s fashion trends are making a comeback in 2017
-
Endpoints News3 months ago
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
-
Uncategorized9 years agoAccording to Dior Couture, this taboo fashion accessory is back
-
Uncategorized9 years agoPhillies’ Aaron Altherr makes mind-boggling barehanded play
-
Uncategorized3 months agoNovartis buys Synnovation’s PI3Kα inhibitors for $3 billion
-
Uncategorized9 years agoUber and Lyft are finally available in all of New York State
-
Uncategorized9 years agoSteph Curry finally got the contract he deserves from the Warriors
-
Contributors9 years agoThe final 6 ‘Game of Thrones’ episodes might feel like a full season